effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200406046968N3

Enrollment

Registered

2020-05-08

Start date

2020-04-29

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 diseaese. COVID-19, virus not identified

Interventions

Intervention 1: Intervention group: 30 COVID-19 patients with inclusion criteria will be treated with 250 micro grams of betafron (Zifron Zist Darou Danesh) Subcutaneously every other day up to 10

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: respiratory rate> 24 / min pao2 / Fio2< 300

Exclusion criteria

Exclusion criteria: Pregnancy history of Sensitivity to interferon-beta 1 compounds (zifron) History of advanced liver disease and liver enzymes three times normal history of severe depression or suicidal thought

Design outcomes

Primary

Measure	Time frame
Oxygenation. Timepoint: daily. Method of measurement: pulse oximetery.	—

Secondary

Measure	Time frame
P/F ratio. Timepoint: daily. Method of measurement: ABG.;Need for mechanical ventilation. Timepoint: daily. Method of measurement: file.;In hospital mortality. Timepoint: daily. Method of measurement: file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMikaeili Haleh

Tabriz University of Medical Sciences

halehmikaeili@gmail.com+98 41 3329 6024

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026